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The childhood cancer embryonal rhabdomyosarcoma can arise in tissuewithout skeletal muscle elements. In
this issue of Cancer Cell, Hatley and colleagues report that non-skeletal muscle progenitors can be a cell of
origin for Sonic Hedgehog-driven embryonal rhabdomyosarcoma in an adipocyte-restricted conditional
mouse model.One of the most intriguing clinical and
scientific questions in pediatric oncology
is how rhabdomyosarcoma, a tumor with
a myogenic phenotype, can arise in tissue
without hypaxial-like skeletal muscle
elements. This conundrum is especially
evident for the embryonal subtype of
rhabdomyosarcoma (eRMS), which can
arise from the salivary glands, skull base
(parameninges), biliary tree, and genito-
urinary tract (bladder/prostate) (Gurney
et al., 1999; Shapiro and Bhattacharyya,
2006). The work by Hatley et al. (2012) in
this issue of Cancer Cell begins to
address this conundrum by highlighting
the plasticity of cells traditionally thought
to be in the adipogenic lineage.
In this paper, Hatley et al. (2012) condi-
tionally activate a mutant Smoothened
(SmoM2) allele to drive Hedgehog sig-
naling in the adipogenic lineage using
a 5.4 kb promoter/enhancer fragment
from the adipocyte fatty acid binding
protein 4 gene (Fabp4, also called aP2)
to drive Cre. Eighty percent of aP2-Cre;
SmoM2/+ mice developed eRMS in the
head and ventral neck by 2 months of
age. aP2-Cre Cdkn2aFlox/Flox mice did
not develop eRMS, whereas deletion of
Cdkn2a in aP2-Cre;SmoM2/+ mice de-
creased latency and increased tumor
penetrance, with all mice having tumors
by 55 days. This finding implicates
Cdkn2a locus loss as a secondary factor
(disease modifier) of eRMS progression.
The authors validated tumors as true
eRMS by histology and immunohisto-
chemistry (Desmin, MyoD, and Myoge-
nin). Similarly, an embryonal muscle
gene signature (MyoD1, Myogenin, Pax7,
Myf5, Myh3, and Myh8) was evident by
RT-PCR assay. To further affirm the diag-
nosis, Hatley et al. (2012) performed gene
expression profiling of aP2-Cre;SmoM2/+tumors in comparison to human eRMS
and tumors of previously reported mouse
eRMS models. Overall, 67% of the probe
pairs and 58% of the ortholog gene
pairs showed agreement in gene expres-
sion between their mouse tumors and
previously published eRMS models (Ru-
bin et al., 2011) or human tumors, respec-
tively. Hatley et al. (2012) concluded that,
despite being of an adipogenic lineage of
origin, aP2-Cre;SmoM2/+ mouse tumors
are an accurate preclinical eRMS model
based on these histological and transcrip-
tome parameters.
The most interesting aspect of this
paper is that these tumors originated
from aP2 expressing cells. Previously,
activity of the aP2 promoter in transgenic
mice has been documented as specific
for the adipocyte lineage and to be
distinct from any skeletal muscle lineage
(Urs et al., 2006). Moreover, the specific
aP2-Cre transgenic line used by Hatley
et al. (2012) was shown to be active in
adipose tissue but not in skeletal muscle,
at least as evidenced from recombination
in the sternocleidomastoid muscle (SCM)
of aP2-Cre;R26-LacZ reporter mice and
aP2-Cre;R26-YFP mice and whole-tissue
examination. Interestingly, it was found
that eRMS tumors in situ were completely
surrounded by non-neoplastic adipose
tissue adjacent to and clearly separated
from the SCM at P14.
To compare the tumorigenic potential
of SmoM in myogenic lineages, Hatley
et al. (2012) activated the SmoM2 allele in
early muscle development, employing
Pax3-, Myf5-, or MyoD1-Cre. All of these
crosses resulted in embryonic lethality
without tumor formation. However, acti-
vation of SmoM2 with Myogenin-Cre,
which is specific for myoblast-stage
muscle differentiation, resulted in tongueCancer Cell 22tumors in 100% of the mice. Mice with
activation of SmoM2 in terminally differen-
tiated skeletal muscle (MCK-Cre) were
viable with no evidence of tumorigenesis.
This result is the best by far in asking
whether differentiated versus differenti-
ating myofibers can transform into rhab-
domyosarcoma. To address the tumori-
genic potential of SmoM2 in postnatal
muscle stem cells (satellite cells), a Pax7-
CreERT2 was employed, and mice were
aged until 150 days—without develop-
ment of tumors. It would have been
intriguing to see if prior reports of non-
myogenic sarcomas arising from a satel-
lite cell lineage (Rubin et al., 2011) would
have been observed if the mice had
been aged longer. Another caveat of
these findings is that the promoter of
SmoM2 in this system was Rosa26, not
the native Smo promoter, and it is there-
fore difficult to say that this is amolecularly
physiological eRMS model. Furthermore,
given that most Hedgehog pathway inhib-
itors currently in clinical trials are Smooth-
ened antogonists, this model may have
highest value as a genetic model of
eRMS for the time being and as a preclin-
ical therapeutic model only when GLI
inhibitors emerge as clinical candidate
agents.
Taking a look onto mesenchymal
progenitor cell biology, the plasticity of
these stem cells may not be so surprising.
It is known that Myf5 expressing cell can
develop into both muscle and brown fat
tissue via PRDM16 and PPARg signaling
(Seale et al., 2008). Furthermore, satellite
cells can undergo adipogenesis under
certain experimental conditions (Asakura
et al., 2001; Shefer et al., 2004) or may
apparently undergo transdifferentiation
into fibroblasts (Brack et al., 2007).
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Figure 1. Model of Skeletal Myogenesis and Possible Cellular
Origins of eRMS
Postnatal muscle maintenance and regeneration are regulated by Pax3, Pax7,
and muscle regulatory factors (MyoD, Myf5, Myogenin, and Myf6). Studies
described in the text suggest that the cells of origin for eRMS include differen-
tiating myoblasts and adipocytes.
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et al., 2006). Such reports
lend one to speculate that
the origin of aP2-Cre;
SmoM2/+ mice tumors might
be cells that have undergone
a transdifferentiation event
from the adipocyte to the
myogenic lineage (Figure 1).
Hatley et al. (2012) recapit-
ulate another important find-
ing by gene expression pro-
filing that aP2-Cre;SmoM2/+
tumors show an activated
satellite cell phenotype re-
flective of the eRMS tumor
pathology rather than the
lineage of origin for the
tumor. Certainly, activation
of Hedgehog signaling was
evident by RT-PCR studies
of aP2-Cre;SmoM2/+ tumors,
yet, by contrast, less than
30% of human eRMS exhibit
a gene expression signature
consistent with a Hedgehog
pathway on overdrive state
(Rubin et al., 2011), and only
rarely is Hedgehog overdrive
a solitary signaling abnor-
mality. Instead, p53 loss of
function was most frequent
(Rubin et al., 2011)—implying
that p53 loss precedesHedgehog overdrive temporally in rhab-
domyosarcomagenesis. The p53 status
of aP2-Cre;SmoM2/+ tumors was unex-
plored, but it would have been of interest
to have known the p53 status of these
tumors, particularly given the 1969 histor-
ical precedent of Li and Fraumeni
describing a familial eRMS syndrome
now known to be attributable to germline
p53 mutation.
In the Hatley model, eRMS tumors
occurred from only the head and neck,
yet human eRMS occur also in the
urogenital tract, extremities, and retro-
peritoneum. Nevertheless, this cranial-
oriented eRMS model may be of specific
interest for the subset of head and neck422 Cancer Cell 22, October 16, 2012 ª2012eRMS patients it models, and closer
examination of the preneoplastic and
early neoplastic lesions will invariably
help us understand the microenvironment
in which these tumor initiating cells
transform.
Overall, the heterogeneity in human
rhabdomyosarcoma phenotypes may
result from the balance between genetic
factors (mutational profile of the tumor
including the initial mutation[s] and modi-
fiers) and epigenetic factors (the cell of
origin). In an era of precision medicine,
this transgenic model representing the
subset of human head and neck ERMS
not derived from myogenic precursors
may be particularly valuable in definingElsevier Inc.therapeutic targets for select
patients. Applying knowledge
from these specialized pre-
clinical models to clinical use
will no doubt require novel
statistical designs for clinical
trials, given that the overall
annual incidence of pediatric
rhabdomyosarcoma is only in
the hundreds, not thousands.
Personalized rhabdomyosar-
coma science inches ever
closer.
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